Along the same lines, the PIK3CA-inhibitor alpelisib has been approved for treatment of hormone receptor positive, HER2-negative metastatic breast cancer further supporting the impact PI3K-signaling has in the luminal subtypes once endocrine resistance has kicked in [92] and supports the concept of targeting the ERBB signaling network also in HER2-low cancer conditions [93]. The gene discussed is NR4A1; the disease is cancer.